UBS’s Northwest Biotherapeutics, Inc. Common stock NWBO Stock Holding History

UBS’s Portfolio NWBO Stock Details NWBO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q3	$92K	Sell	18,428 -31,469	-63%	-$193K	﹤0.01%	6097
2014 Q2	$335K	Sell	49,897 -85,501	-63%	-$544K	﹤0.01%	4623
2014 Q1	$981K	Buy	135,398 +90,374	+201%	+$536K	﹤0.01%	3509
2013 Q4	$169K	Buy	45,024 +42,212	+1,501%	+$163K	﹤0.01%	5488
2013 Q3	$9K	Hold	2,812	–	–	﹤0.01%	8983
2013 Q2	$9K	Buy	+2,812	New	+$10.2K	﹤0.01%	8807

Other funds holding NWBO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

UBS's NWBO Position: Q3 2014 in Review

UBS reduced its Northwest Biotherapeutics, Inc. Common stock (NWBO) stake by 63% in Q3 2014, selling an estimated $193K and leaving 18,428 shares worth $92K. The position accounts for ﹤0.01% of the portfolio, ranked #6097.

UBS first reported a position in NWBO in Q2 2013 and has held it in 6 quarters since. The position peaked at $981K in Q1 2014. 71 funds tracked by Wall St. Rank hold NWBO as of Q3 2014.

UBS held 18,428 shares of Northwest Biotherapeutics, Inc. Common stock worth $92K as of Q3 2014.
UBS sold 31,469 Northwest Biotherapeutics, Inc. Common stock shares in Q3 2014, an estimated $193K.
Northwest Biotherapeutics, Inc. Common stock made up ﹤0.01% of UBS's portfolio in Q3 2014, its #6097 holding.
UBS first reported a position in Northwest Biotherapeutics, Inc. Common stock in Q2 2013 and has held it in 6 quarters since.
UBS's Northwest Biotherapeutics, Inc. Common stock position peaked at $981K in Q1 2014.
71 funds tracked by Wall St. Rank held Northwest Biotherapeutics, Inc. Common stock as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.